Skip to main content

Venous Thromboembolism clinical trials at UC Health
10 in progress, 8 open to new patients

  • A Comparison Study of Oral Anticoagulants (blood thinners) for Extended VEnous Thromboembolism (blood clot in vein)

    open to eligible people ages 18 years and up

    Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.

    at UC Irvine

  • A Study of Experimental Blood Thinner "Dabigatran" for Treatment of Venous Thromboembolism in Children

    open to eligible people ages up to 17 years

    The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate dosing algorithm for use in patients from birth to less than 18 years of age.

    at UC Davis

  • Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

    open to eligible people ages 18 years and up

    The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant options, and the impact of venous thromboembolism on patient-defined outcomes, such as quality-of-life, symptom burden, and treatment satisfaction. This information is crucial to helping clinicians and patients choose between various treatment options for venous thromboembolism in order to achieve the best possible balance between the risks, benefits, and impact on health.

    at UCSF

  • Apixaban for the Acute Treatment of Venous Thromboembolism in Children

    open to eligible people ages up to 17 years

    To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

    at UCSF

  • Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

    open to eligible people ages 21 years and up

    The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.

    at UCSF

  • Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

    open to eligible people ages up to 17 years

    This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.

    at UCLA

  • Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

    open to eligible people ages up to 18 years

    This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and to compare if these effects are similar to those observed in adults.

    at UCLA

  • Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

    open to eligible people ages up to 18 years

    This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.

    at UC Davis

  • EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.

    at UCLA

  • Women's Health Initiative Strong and Healthy Study

    Sorry, in progress, not accepting new patients

    The WHISH trial applies state-of-the science behavioral principles and currently available technologies to deliver a physical activity intervention without face-to-face contact to ~25,000 older U.S. women expected to consent. It includes the National Institute of Aging (NIA) Go4Life® Exercise & Physical Activity materials 3 and WHISH developed targeted materials based on Go4Life® to provide inspirational tips and recommendations about how to achieve nationally recommended levels of PA and overcome barriers to exercise, with a means for self-monitoring and setting personal goals. The intervention builds upon evidence-based behavioral science principles and intervention components that have proven to be effective in increasing PA in older women, with innovative adaptive approaches to tailoring the delivery to meet individual (personal) needs.

    at UCSD

Last updated: